HRSA-21-032: Sickle Cell Disease Treatment Demonstration Program
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Health Resources and Services Administration notices from 2021.
Health Resources and Services Administration offered grants to the applicants described in the notice. It expected to make about 5 awards worth $5.0 million in total. Applications closed on May 3, 2021.
From the official notice on Grants.gov, last changed February 23, 2021. Checked November 7, 2026.
- Total funding$5.0 million
- Expected awards5
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | February 23, 2021 |
|---|---|
| Deadline | May 3, 2021 |
| Archived by Grants.gov | July 2, 2021 |
Who can apply
This opportunity was open to the applicants described in the notice.
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Eligible applicants include a Federally-qualified health center, a nonprofit hospital or clinic, or a university health center that provides primary health care, that has a collaborative agreement with a community-based sickle cell disease organization or a nonprofit entity with experience in working with individuals who have sickle cell disease; and demonstrates to the HRSA Administrator that either the federally-qualified health center, the nonprofit hospital or clinic, the university health center, the organization or entity described in clause (i) 42 USC § 300b-5, or experts as described in paragraph (2)(C) of 42 USC § 300b-5, has at least five (5) years of experience in working with individuals who have sickle cell disease. Federally-qualified health center is defined in section 1905(l)(2)(B) of the Social Security Act (42 U.S.C. 1396d(l)(2)(B)).
Is this a realistic fit?
- No cost sharing or match is required.
What the grant funds
This notice announces the opportunity to apply for funding under the Sickle Cell Disease Treatment Demonstration Program (TDP). The purpose of the TDP is to increase access for individuals with sickle cell disease (SCD) to quality, coordinated, comprehensive care by: 1) increasing the number of clinicians or health professionals knowledgeable about the care of SCD, 2) improving the quality of care provided to individuals with SCD, and 3) improving care coordination with other providers.
Who has won Sickle Cell Treatment Demonstration Program grants before
From fiscal 2021 to 2025, Sickle Cell Treatment Demonstration Program (93.365) awarded $27.0 million across 5 grant awards, an average of $5.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| University of Alabama at Birmingham | Alabama | 1 | $6.2 million |
| The Johns Hopkins University | Maryland | 1 | $6.2 million |
| The Washington University | Missouri | 1 | $5.0 million |
| Childrens Hospital Medical Center | Ohio | 1 | $5.0 million |
| The Center for Comprehensive Care & Diagnosis of Inherited Blood Disorders | California | 1 | $5.0 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is HRSA-21-032 still open?
No. It closed on May 3, 2021.
Who can apply for Sickle Cell Disease Treatment Demonstration Program?
Health Resources and Services Administration accepted applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.
What is the deadline for Sickle Cell Disease Treatment Demonstration Program?
Closed May 3, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $5.0 million in total across about 5 awards.
Who has won Sickle Cell Treatment Demonstration Program grants before?
The largest recipients over five fiscal years were University of Alabama at Birmingham, The Johns Hopkins University, The Washington University. The program made 5 awards worth $27.0 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)